Uvax Bio LLC
Uvax Bio is a vaccine company founded in 2018, originating from Scripps Research, focusing on developing prophylactic vaccines for challenging infectious diseases using proprietary platform technology. Their mission is to solve global infectious disease threats through rational antigen design and protein engineering, aiming to become a leader in the vaccine industry and address unmet public health needs.
Industries
Nr. of Employees
small (1-50)
Products
Recombinant protein nanoparticle vaccine candidates for HIV-1
Protein nanoparticle vaccine candidates designed to present stabilized envelope trimers to elicit neutralizing antibody responses; advanced into Phase I clinical testing with interim safety and immunogenicity results reported.
Pipeline vaccine programs for multiple pathogens (preclinical and development stage)
Vaccine programs in development employing protein nanoparticle display and antigen engineering against pathogens including hepatitis C virus, RSV, hMPV, influenza, parainfluenza, Zika, dengue, Lassa, Ebola, Marburg, tuberculosis, and malaria.
Recombinant protein nanoparticle vaccine candidates for HIV-1
Protein nanoparticle vaccine candidates designed to present stabilized envelope trimers to elicit neutralizing antibody responses; advanced into Phase I clinical testing with interim safety and immunogenicity results reported.
Pipeline vaccine programs for multiple pathogens (preclinical and development stage)
Vaccine programs in development employing protein nanoparticle display and antigen engineering against pathogens including hepatitis C virus, RSV, hMPV, influenza, parainfluenza, Zika, dengue, Lassa, Ebola, Marburg, tuberculosis, and malaria.
Services
Design and preclinical development of recombinant protein nanoparticle vaccine candidates using structure-based antigen engineering and multivalent nanoparticle display.
Developing research cell banks and streamlined expression and purification processes to enable production of complex protein nanoparticle vaccines at scales suitable for clinical studies.
Management and conduct of early-phase clinical trials including regulatory submissions, site partnerships, participant dosing, safety monitoring, and immunogenicity assessments.
Design and preclinical development of recombinant protein nanoparticle vaccine candidates using structure-based antigen engineering and multivalent nanoparticle display.
Developing research cell banks and streamlined expression and purification processes to enable production of complex protein nanoparticle vaccines at scales suitable for clinical studies.
Management and conduct of early-phase clinical trials including regulatory submissions, site partnerships, participant dosing, safety monitoring, and immunogenicity assessments.
Expertise Areas
- Vaccine design and development
- Protein nanoparticle platforms
- Antigen engineering and glycan modification
- Preclinical immunology and animal studies
Key Technologies
- Structure-guided antigen design
- Self-assembling protein nanoparticles
- Glycan trimming and glycoprotein engineering
- Recombinant protein expression
News & Updates
UVAX Bio received a $2.6 million investment from CEPI to advance its MERS vaccine candidate into preclinical trials, with nanoparticle design mimicking the size and shape of MERS virus to trigger an enhanced immune response.
Uvax Bio announced the appointment of Kevin O’Neill as Interim CEO, succeeding Ji Li, Ph.D.
The UVAX-1107 protein nanoparticle vaccine was safe and well-tolerated in healthy volunteers, with robust IgG antibody responses after two priming doses.
The first participant has been dosed in a Phase 1 trial of HIV-1 vaccine candidates UVAX-1107 and UVAX-1197 in Australia.
The company received approval from Australian authorities to conduct a Phase 1 study in Australia, starting in January 2024.
Dr. Jiang Zhu will present a review of Uvax Bio’s HIV-1 vaccine development, including preclinical safety and immunogenicity results.
UVAX Bio received a $2.6 million investment from CEPI to advance its MERS vaccine candidate into preclinical trials, with nanoparticle design mimicking the size and shape of MERS virus to trigger an enhanced immune response.
Uvax Bio announced the appointment of Kevin O’Neill as Interim CEO, succeeding Ji Li, Ph.D.
The UVAX-1107 protein nanoparticle vaccine was safe and well-tolerated in healthy volunteers, with robust IgG antibody responses after two priming doses.
The first participant has been dosed in a Phase 1 trial of HIV-1 vaccine candidates UVAX-1107 and UVAX-1197 in Australia.
The company received approval from Australian authorities to conduct a Phase 1 study in Australia, starting in January 2024.
Dr. Jiang Zhu will present a review of Uvax Bio’s HIV-1 vaccine development, including preclinical safety and immunogenicity results.